Activated c-Abl tyrosine kinase in malignant solid tumors.
Mutant forms of the c-ABL gene are well known to be involved in hematopoietic malignancies such as chronic myeloid leukemia (CML). CML patients possess a fused BCR-ABL gene that activates the Abl tyrosine kinase domain within Bcr-Abl. In general fusion proteins that cause oligomerization of Abl lead to activation of its tyrosine kinase activity. In this review, we highlight recent discoveries indicating that the activated c-Abl tyrosine kinase, not as a fusion protein, plays an important role in malignant solid tumors of lung and breast.
Lin
J
J
Department of Molecular Pathology, MD Anderson Cancer Center, University of Texas, Houston, TX 77054, USA.
Arlinghaus
R
R
D001943:Breast Neoplasms / Q000201:enzymology* / Q000209:etiology / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology* / Q000209:etiology / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004789:Enzyme Activation; D066246:ErbB Receptors / Q000502:physiology; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology* / Q000209:etiology / Q000473:pathology; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics / Q000502:physiology*; D011519:Proto-Oncogenes; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000502:physiology
C499993:TUSC2 protein, human; D025521:Tumor Suppressor Proteins; D066246:ErbB Receptors; D016315:Proto-Oncogene Proteins c-abl